Enterprise Value
187M
Cash
21.79M
Avg Qtr Burn
N/A
Short % of Float
0.02%
Insider Ownership
13.81%
Institutional Own.
34.76%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Inhaled AAT Details Severe alpha-1 antitrypsin deficiency | Phase 3 Update | |
Failed Discontinued |